Series B · Biotech

Marrow Therapeutics raises $120m Series B for bone marrow-targeted medicines

OrbiMed led the round as Marrow advances its lead program for sickle cell disease and beta thalassemia.

Marrow Therapeutics announced a $120 million Series B led by OrbiMed on 17 November 2026. Returning Series A investors and new institutional backers participated. The company separately disclosed its earlier $53 million Series A, bringing combined financing to $173 million. Marrow is advancing MAR-101 through studies preparing for clinical development in sickle cell disease and beta thalassemia.

Use of funds

Develop bone marrow-targeted genetic medicines

Advance MAR-101 toward clinical development

Funding history

Series B · This round$120M

Sources

  1. Marrow Therapeutics Launches with $173 Million to Develop Genetic Medicines for Bone Marrow Disordersmarrowtx.com · Nov 17, 2026